The concern about soy and breast cancer originated from animal studies in which isolated soy isoflavones given at pharmacological doses promoted tumour growth in oestrogen-sensitive cell lines. This laboratory finding does not translate to human dietary exposure. In human prospective studies, soy consumption is associated with reduced breast cancer risk in Asian populations and neutral or reduced risk in Western populations.
The Human Evidence
- Shanghai Women's Health Study: followed 73,000 women for 7 years; those with the highest soy intake had a 59 percent lower risk of premenopausal breast cancer compared to lowest intake
- UK Biobank analysis: 272,000 women followed prospectively; soy intake was not associated with increased breast cancer risk in either pre- or post-menopausal women in Western populations
- Breast cancer survival: a meta-analysis of 9,514 breast cancer survivors found that higher post-diagnosis soy intake was associated with significantly lower recurrence risk and lower all-cause mortality
- Isoflavone mechanism: soy isoflavones act as selective oestrogen receptor modulators, binding predominantly to beta receptors that have anti-proliferative effects in breast tissue, not the alpha receptors that drive oestrogen-dependent tumour growth
The Safe Practical Conclusion
The evidence supports moderate whole food soy consumption (tofu, edamame, tempeh, and miso) as safe and potentially protective for most women including breast cancer survivors. High-dose isolated isoflavone supplements remain a different question. NutritionFacts.org reviews the evidence as supporting up to 3 to 5 servings of whole food soy products daily as safe for women with and without a history of hormone-sensitive cancer.